<sup>18</sup>F-FDG PET/CT显像评估非小细胞肺癌EGFR基因突变的研究现状

doi:10.3969/j.issn.1671-7171.2020.07.001

摘要
图/表
参考文献
相关文章 (15)

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018, 68(6): 394-424.
[2] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2019, 41(1): 19-28.
[3] Pao W, Girard N. New driver mutations in non-small-cell lung cancer[J].Lancet Oncol,2011, 12(2): 175-180.
[4] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010, 362(25): 2380-2388.
[5] Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomized, phase 3 trials[J].Lancet Oncol,2015, 16(2):141-151.
[6] Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005, 352(8): 786-792.
[7] 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组.中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J].中华病理学杂志,2016,45(4):217-220.
[8] Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J].J Thorac Oncol,2012,7(1):115-121.
[9] Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status[J].J Thorac Oncol,2014,9(9):1345-1353.
[10] 罗丹静,马进安,张锦明,赵颜忠.非小细胞肺癌EGFR突变的分子影像学在体检测[J].中国肺癌杂志,2017,20(6):415-420.
[11] 原发性肺癌诊疗规范(2018年版)[J].肿瘤综合治疗电子杂志, 2019, 5(3): 100-120.
[12] Kurata T, Oguri T, Isobe T, et al. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases[J].Jpn J Cancer Res,1999, 90(11): 1238-1243.
[13] Sasaki H, Shitara M, Yokota K, et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas[J].Mol Med Rep,2012, 5(3): 599-602.
[14] Mamede M, Higashi T, Kitaichi M, et al. [¹⁸F] FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung[J].Neoplasia, 2005, 7(4): 369-379.
[15] Kaira K, Serizawa M, Koh Y, et al. Biological significance of ¹⁸F- FDG uptake on PET in patients non-small-cell lung cancer[J].Lung Cancer,2014, 83 (2):197-204.
[16] Kazuya T, Kaoru M, Hideya K, et al. Correlation of EGFR or KRAS mutation status with ¹⁸F-FDG uptake on PET-CT scan in lung adenocarcinoma[J].PLoS One,2017, 12(4): e0175622.
[17] 胡娜, 王云华. ¹⁸F-FDG PET/CT代谢参数在肺癌中的应用[J].中华核医学与分子影像杂志, 2018(1): 59-63.
[18] Na II, Byun BH, Kim KM, et al. ¹⁸F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis[J].Lung Cancer,2010, 67: 76-80.
[19] Guan J, Xiao NJ, Chen M, et al. ¹⁸F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer[J].Medicine,2016, 95(30): e4421.
[20] Takamochi K, Mogushi K, Kawaji H, et al. Correlation of EGFR or KRAS mutation status with ¹⁸F-FDG uptake on PET-CT scan in lung adenocarcinoma[J].PLoS One,2017, 12(4): e0175622.
[21] Lv Z, Fan J, Xu J, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients[J].Eur J Nucl Med Mol Imaging,2018, 45(5): 735-750.
[22] Huang CT, Yen RF, Cheng MF, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma[J].Med Oncol,2010, 27(1): 9-15.
[23] Lee Y, Le HJ, Kim YT, et al. Imaging Characteristics of Stage Ⅰ Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival[J].Korean J Radiol,2013, 14(2): 375-383.
[24] Caicedo C, Garcia-velloso MJ, Lozano MD, et al. Role of [¹⁸F] FDG PET in prediction of KRAS, and EGFR, mutation status in patients with advanced non-small-cell lung cancer[J].Eur J Nucl Med Mol Imaging,2014, 41(11): 2058-2065.
[25] Liu A, Han A, Zhu H, et al. The role of metabolic tumor volume (MTV) measured by [¹⁸F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer[J].Oncotarget,2017, 8(20): 33736-33744.
[26] Kim YI, Paeng JC, Park YS, et al. Relation of EGFR mutation status to metabolic activity in localized lung adenocarcinoma and its influence on the use of FDG PET/CT parameters in prognosis[J].AJR Am J Roentgenol,2018, 210(6): 1346-1351.
[27] 姜阳, 马晓伟, 董楚宁, 等. 基于¹⁸F-FDG PET-CT代谢参数的风险模型对非小细胞肺癌EGFR基因突变的预测价值及效能评价 [J] .中华放射学杂志,2020,54(7): 688-693.
[28] Zhang J, Zhao X, Zhao Y, et al. Value of pre-therapy ¹⁸F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer[J].Eur J Nucl Med Mol Imaging,2020, 47(5): 1137-1146.